Skip to content

Danish Life Sciences Forum

Danish Life Sciences Forum Brand


The Danish Trade Council Lundbeck Canada Inc. Novo Nordisk Canada Inc. LEO Pharma Inc. Canada


Formalized in March 2018, the Danish Life Sciences Forum is a group of three Danish pharmaceutical affiliates in Canada (Novo Nordisk Canada, Lundbeck Canada, and LEO Pharma) who all share a similar interest in the long-term sustainability of the innovative life sciences industry in Canada.

Danish Life Sciences Forum members are all foundation-based companies. These foundations have a mandate to develop social and economic benefits to all and not just the shareholders. A substantial portion of their revenue is redirected to support research and education as well as contribute to civil society, culture, and the economy.

The Forum is committed to engaging with public and private sector stakeholders in Canada to help ensure that the life sciences industry continues to be an important source of jobs, economic growth, and improved health outcomes for Canadians.

Opportunities and Challenges

Denmark and Canada not only share a physical 4,000 km border, but they also have many other similarities, including standard of living, business culture, societal values, as well as a general ambition to be ahead of the curve when it comes to finding innovative solutions to problems.

We believe that given our similarities, we have a lot that we can learn from each other, including our approaches to creating a business-friendly environment and regulatory framework that allows for innovation, better access, and growth in the life sciences sector.

News and Events

Growing the Life Sciences Industry: Improving Access, Affordability & Appropriate Use of Medicines

On September 25, 2018, a moderated discussion took place in Ottawa to look at examples from Canada and Denmark on approaches for improving affordability of and access to innovative medicines, while at the same time growing the knowledge-based economy. The event was moderated by Ilse Treurnicht, Former CEO, MaRS Discovery District and opening remarks were delivered by the Danish Ambassador to Canada, Thomas Winkler. Panellists included Hans Erik Henriksen, CEO Healthcare Denmark, Brian Hilberdink, President, Novo Nordisk Canada Inc., and Sheryl Groeneweg, Director General, Manufacturing & Life Sciences Branch Innovation, Sciences and Economic Development Canada.

Click here to watch the full event and discussion.

Treasury Board Secretariat’s regulatory modernization initiative submission – September 14, 2018

The Danish Life Sciences Forum provided input on the Treasury Board Secretariat’s regulatory modernization initiative. The submission is complementary to that of the industry association, Innovative Medicines Canada (IMC), and focuses on one of the three key sectors that have been targeted for the three-year regulatory review process: health and bio-sciences. The submission focuses on Health Canada’s proposed reform of the PMPRB, which runs contrary to the Treasury Board Secretariat’s efforts to streamline regulation in health and bio-sciences. Please review the full submission here.

Danish Life Sciences Forum provides input to the Advisory Council on the Implementation of National Pharmacare

On Friday, September 28, Danish Life Sciences Forum provided input on the Advisory Council's implementation of National Pharmacare. The input submission is complementary to that of the industry association, Innovative Medicines Canada (IMC), and provides a Danish perspective on the national pharmacare discussions, conveying six specific recommendations for the Advisory Council's further development of a national pharmacare system in Canada. Please find the full input submission here.  

Pre-Budget Submission

In response to the Pre-Budget Consultations in advance of the 2019 budget launched by the Standing Committee on Finance, the Danish Life Sciences Forum submitted recommendations to support the topic of Economic Growth: Ensuring Canada's Competitiveness. The Danish Life Sciences Forum has offered its perspectives on how the federal government can use innovation in the life sciences industry as a way to diversify the economy, increase productivity and competitiveness, and attract and retain the jobs of tomorrow. Please review the full pre-budget submission here.

Denmark Launches a Life Sciences Growth Plan

Denmark has launched a new growth plan for life sciences, which aims to strengthen one of Denmark's leading industries. The plan includes 36 initiatives, targeting barriers and opportunities for the industry across the entire value chain. Although Danish life sciences companies are already leading in global markets, there is general recognition that in order to remain competitive, it requires a constant focus on strengthening innovation, research and product development.





contact uS:

Kerry Allerton

Senior Trade Advisor
Healthcare and Life Sciences
001 (416) 640 1301